Author Archives: Mary Chapman

CureDuchenne Ventures Invests in Dyne and Its DMD Therapy Program

A CureDuchenne Ventures equity investment will support Dyne Therapeutics in developing precision treatments aimed at repairing muscles in Duchenne and other muscular dystrophies. The funding — whose amount was not disclosed — will help to advance the company’s efforts to target the genetic makeup of Duchenne muscular dystrophy (DMD), with a goal…